Seattle, WA May 16, 2016 – Kineta, Inc., a biotechnology company focused on the translational development of novel antiviral and immune modulating drugs presented promising new data on Kineta’s vaccine adjuvant program at the American Association of Immunologists annual meeting in Seattle, WA.

Dr. Peter Probst, Director and Head of Immunology, presented data demonstrating the unique protective immune response of Kineta’s vaccine adjuvants and dose sparing efficacy achieved in vivo. Kineta’s lead adjuvant is being developed in combination with H5N1 influenza antigens to provide a safe and more efficacious vaccine.

“We are very excited to have a strong presence at the Immunology 2016 conference with multiple presentations on Kineta’s vaccine adjuvant program,” stated Kristin Bedard, VP R&D and Head of Virology at Kineta. “Our immune modulating vaccine adjuvants were discovered using Kineta’s AViiD™ screening platform. This proprietary platform identifies small molecules that trigger an IRF-3 response – a novel target for immune modulating adjuvants and therapeutics.”

About Kineta’s Vaccine Adjuvant Program

Kineta is developing novel immune modulating adjuvants that enhance the efficacy of existing vaccines through a balanced immune response while using lower vaccine doses. The lead compound is in preclinical development. It was discovered through Kineta’s proprietary AViid™ discovery platform which is focused on screening for small molecules that activate IRF-3 dependent innate immune pathways. Kineta’s vaccine adjuvants provide a targeted approach that safely stimulates innate immune protective pathways. This adjuvant system targets highly pathogenic avian influenza infection and may have application in other critical infectious diseases. This program is conducted in collaboration with the National Institutes of Health (NIH) and University of Washington.

About Kineta

Kineta, Inc. is an emerging and sustainable biotech company that fills a void in the biopharmaceutical industry by efficiently advancing therapies from discovery to clinical proof of concept. We actively collaborate with a broad array of private, government and industry partners to advance our innovative research in autoimmune diseases, antivirals and chronic pain. Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. For more information on Kineta, Inc. visit our website, www.Kinetabio.com

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, intellectual property protection and enforcement, efficacy and demand for our products, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and changes in legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.